Elevation Oncology, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Elevation Oncology, Inc. has finalized its merger with Concentra Biosciences, LLC's subsidiary, resulting in the company becoming a private entity and its shares being delisted from Nasdaq.
Elevation Oncology, Inc. has terminated its License Agreement with CSPC Megalith Biopharmaceutical Co., Ltd. for the Claudin 18.2 antibody-drug conjugate EO-3021, following the discontinuation of its development.
8-K: Elevation Oncology to Be Acquired by Concentra Biosciences in Cash and Contingent Value Rights Deal
Elevation Oncology, an innovative oncology company, has entered into a definitive merger agreement to be acquired by Concentra Biosciences for $0.36 per share in cash plus a non-tradeable contingent value right tied to net cash and future disposition of its HER3 ADC product candidate, EO-1022.
Elevation Oncology reported its Q1 2025 financial results, highlighting preclinical data for EO-1022 and a cash runway into the second half of 2026.
Elevation Oncology voluntarily prepaid its $32.3 million term loan, fully discharging all related obligations and releasing security interests on its assets.
Elevation Oncology announces its intention to prepay its $30 million term loan, plus fees and interest, totaling approximately $32.2 million, to K2 HealthVentures LLC.
Elevation Oncology announces the departure of Chief Medical Officer Valerie M. Jansen, effective March 31, 2025, and details of her separation agreement.
Elevation Oncology discontinues development of EO-3021, a Claudin 18.2 ADC, while advancing EO-1022, a HER3 ADC, and exploring strategic alternatives to maximize shareholder value.
Elevation Oncology's shares will transfer from The Nasdaq Global Select Market to The Nasdaq Capital Market, granting them an extension until September 15, 2025, to regain compliance with Nasdaq's minimum bid price requirement.
Elevation Oncology reports its financial results for Q4 and the full year 2024, highlighting progress in its clinical programs, including the Claudin 18.2 ADC (EO-3021) and HER3 ADC (EO-1022).
Elevation Oncology announces the resignation of Chief Scientific Officer, David Dornan, Ph.D., effective February 17, 2025.
Elevation Oncology provided updates on its clinical programs, including expected data readouts and a cash runway extending into 2026.
Elevation Oncology announced positive initial Phase 1 clinical data for EO-3021 and its third quarter 2024 financial results, highlighting progress in its clinical programs and a strong cash position.
Elevation Oncology received a notice from Nasdaq that it is not in compliance with the minimum bid price requirement for continued listing, as its share price has fallen below $1.00 for 30 consecutive business days.
Elevation Oncology reported positive initial Phase 1 clinical trial data for EO-3021, showing a 42.8% objective response rate in a subset of gastric and GEJ cancer patients, and announced its second quarter 2024 financial results.
Elevation Oncology held its 2024 Annual Meeting of Stockholders on June 13, 2024, where directors were elected and the company's accounting firm was ratified.
Elevation Oncology announced its first quarter 2024 financial results, highlighting progress in its clinical programs and a strengthened cash position.
Elevation Oncology reports the resignation of Lori Hu from its Board of Directors and the appointment of Darcy Mootz to the Board's Audit Committee.
Elevation Oncology announced its fourth quarter and full year 2023 financial results, highlighting progress in its clinical programs and a strengthened financial position.
Elevation Oncology has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a previous listing deficiency.
Elevation Oncology has appointed Darcy Mootz, Ph.D., to its Board of Directors as a Class II director and member of the Compensation Committee, effective immediately.